accd stock: Accolade overview & 2025 update

This article explains accd stock — the NASDAQ ticker for Accolade, Inc. — covering company background, financials, the 2025 Transcarent merger and delisting, regulatory filings, risks, timeline of ...

2024-07-14 09:54:00

By Cyber Fusion

Article rating

4.3

111 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Accolade, Inc. (ACCD)

Note: This article uses the keyword accd stock throughout to help readers find current and historical information about Accolade, Inc. and its public-trading history. It is written in a neutral, factual style with dated source attributions where available. Not financial advice.

Introduction

As of April 8, 2025, accd stock referred to shares of Accolade, Inc., a U.S.-based, technology-enabled personalized healthcare and benefits navigation company. This guide explains who Accolade is, what accd stock represented while public, the key financial and corporate events in 2024–2025 (including a reported merger with Transcarent and subsequent delisting actions), and where to find authoritative filings and market data. Readers will learn the practical implications of the transaction for former public shareholders and how to track related market updates on platforms such as Bitget.

Company overview

Accolade was founded in 2007 to simplify healthcare navigation for employees and members. The company combined a software platform with clinician-led services to provide benefits navigation, virtual primary care, mental health support, expert medical opinion and other care coordination solutions aimed primarily at employers and health plans.

Headquarters and founding: Accolade was founded in 2007 and was headquartered in the United States. Its core proposition was to help employers and payors improve employee health outcomes and control costs through navigation, advocacy and care access.
Core services: The platform typically combined digital tools with human advocates and licensed clinicians. Services included benefits navigation, virtual primary care, behavioral health services, care coordination, and expert medical review/second opinions.
Customers and business model: The primary customers were employers and health plans purchasing Accolade’s services for their employees or members. Revenue generally came from subscription and service fees tied to contracts with organizations and health plans, producing a platform-plus-service business model.

This summary is based on public company descriptions and market-data profiles recorded in investor pages and filings reported through April 2025 (see References).

Stock and market information

This section explains the trading symbol, where accd stock was listed, and common market metrics investors consulted while the company was publicly traded.

ACCD ticker and exchange

Ticker symbol: The company’s NASDAQ trading symbol was ACCD, often referenced in market commentary as accd stock or $ACCD.
Exchange: Accolade’s shares traded on the NASDAQ exchange while the company remained public.
Market data: Public market-data pages (Investing.com, Yahoo Finance, Barchart, ADVFN, MarketBeat, and others) provided real-time quotes, previous close, intra-day high/low, 52-week range, market capitalization, volume and average volume metrics for accd stock prior to the delisting reported in 2025.

Listing history and trading status

IPO/listing: Accolade completed its IPO and subsequent listing on NASDAQ prior to 2025. Historical company materials and market-data pages record the company’s trading history on NASDAQ until the corporate transaction was completed in 2025.
2025 trading status change: As of March–April 2025, accd stock’s public-trading status changed as a result of a reported merger transaction with Transcarent and subsequent filings notifying regulators and the public of changes to registration and listing status.

Price performance and key metrics

Price and liquidity snapshots: Prior to the corporate transaction in early April 2025, market-data pages listed accd stock price history, 52-week ranges, daily trading volumes and market capitalization estimates. These metrics changed materially around the dates of the merger announcement, shareholder vote and closing.
Valuation metrics: Common metrics reported for accd stock while public included revenue multiples (price-to-sales), earnings per share (EPS — typically negative in recent periods), and cash/adjusted EBITDA metrics used by investors. Trailing and forward P/E ratios were generally not meaningful when EPS was negative. Market commentary and analyst pages (MarketBeat, Yahoo Finance) provided differing target prices and ratings through early 2025.

Note: Market snapshots vary by source and time. Always check the time-stamp on market-data pages when reviewing historical figures for accd stock.

Financial performance

This section summarizes recent public financial performance disclosed in company filings and reported across market-data sites as of early 2025.

Revenue: Trailing twelve months (TTM) revenue figures reported around the company’s last public filings were in the range of approximately $440 million to $447 million (reported figures vary slightly by reporting period and source). Sources for revenue data include company filings and market-data providers with date-stamped snapshots.
Profitability: Accolade reported net losses in recent annual and quarterly periods leading up to 2025; EPS trends were negative on a TTM basis in the public filings and market summaries available through market-data services.
Balance sheet highlights: Public disclosures indicated cash, short-term investments and liquidity balances alongside outstanding debt levels in the company’s SEC filings. The balance-sheet picture, including cash and debt, was a factor in investor assessments of accd stock before the transaction.

All figures above are approximate and tied to the last public reporting periods preceding the merger; readers should consult the company’s SEC filings for exact, period-specific numbers.

Corporate actions and transactions

Accolade’s 2024–2025 corporate actions were the principal drivers of public-market interest in accd stock. The most material events were the agreement and completion of a merger with Transcarent and subsequent delisting actions reported in early April 2025.

Merger with Transcarent

Announcement and terms: Accolade announced a proposed transaction with Transcarent in late 2024 or early 2025 (public sources vary on the exact announcement date). The reported financial consideration for Accolade shareholders in the transaction included a cash component of approximately $7.03 per share as reported by multiple market reports covering the deal.
Shareholder approval: According to public reporting, Accolade shareholders voted to approve the merger on March 27, 2025. Market commentary and company statements noted the approval milestone and next steps toward closing.
Transaction value and rationale: Reports indicated the merger was intended to combine Accolade’s employer-focused navigation and advocacy services with Transcarent’s digital healthcare capabilities to expand scale and product offerings. Reported transaction metrics (cash per share and aggregate transaction value) were cited across market-data pages and press coverage.

As of March 27, 2025, multiple outlets recorded the shareholder vote result; details on the definitive agreement and per-share consideration were included in the company’s proxy materials and subsequent closing disclosures.

Delisting and post-transaction status

Closing and effective date: Accolade and Transcarent publicly announced completion of the transaction on or about April 8, 2025. Following completion, public reporting indicated steps to terminate Accolade’s SEC registration and remove Accolade’s shares from NASDAQ quotation and trading.
Regulatory filings: The company filed required Securities and Exchange Commission forms related to the transaction and termination of public reporting obligations (including filings commonly used for termination of registration such as Form 15-related filings). These filings documented the cessation of public reporting and were part of the public record in April 2025.
Post-transaction ownership: Following the transaction, Accolade became part of a combined or privately held entity under the terms of the transaction (depending on the structure disclosed in SEC filings and company announcements). Public equity that formerly traded under ACCD was no longer available on NASDAQ after the delisting actions took effect.

Readers should consult the company’s Form 8-K, proxy statements and any Form 15 filings for definitive legal text about registration termination and the practical impact on former holders of accd stock.

Governance and management

Executive leadership: Accolade’s public disclosures listed the company’s CEO and senior leadership team leading into 2025. Management and the board participated in negotiation and approval of the merger transaction. Post-closing governance for the combined organization was described in transaction documents and public statements about leadership alignment at the combined entity level.
Board matters: The board’s recommendation to shareholders and any governance changes tied to the merger (such as director appointments or resignations) were documented in proxy materials and 8-K disclosures ahead of the March 27, 2025 shareholder vote.

Specific executive names and board membership referenced in filings should be verified in the company’s SEC filings and press releases from the dates surrounding the transaction.

Ownership and shareholders

Institutional ownership: Prior to the transaction, institutional holders and mutual funds held meaningful stakes in Accolade; institutional ownership percentages were reported by market-data pages and SEC filings (13F disclosures for institutional investors). Large institutional holders commonly appeared in public ownership summaries on data platforms.
Insider ownership: Insiders (executive officers and directors) held positions disclosed in proxy statements and Forms 4/5. Any material insider transactions during the deal period would be documented in these filings.
Post-transaction transfers: The closing of the transaction and delivery of consideration (cash per share, as reported) changed the ownership profile — public shareholders received the agreed consideration and Accolade ceased to trade publicly, removing its ordinary shares from NASDAQ quotation.

Investors seeking precise percentages and lists of holders should consult the company’s final proxy and Schedule 13D/13G/13F filings and the SEC’s EDGAR system for the applicable dates in early 2025.

Analyst coverage and market perception

Sell-side and independent analysts: Analysts who covered accd stock prior to the transaction published ratings and price targets; these varied across firms and were summarized on coverage aggregators (e.g., MarketBeat). Consensus ratings and target ranges changed materially after the merger announcement as the public-equity path closed.
Retail sentiment: Social platforms and retail investor services (Stocktwits, Robinhood community pages and similar social feeds) included commentary on accd stock, merger reaction and trade ideas prior to closing. Sentiment varied by platform and date, with notable spikes in activity around the shareholder vote and closing announcements.
Post-transaction perception: After the closing in April 2025, market commentary shifted from public-market valuation to strategic rationale and integration planning for the combined businesses.

Regulatory filings and compliance

Key SEC filings and regulatory documents that investors and researchers used to verify facts about accd stock and the transaction included (but were not limited to):

Proxy statement and definitive materials used to solicit shareholder votes on the merger (these detailed the terms of the transaction, board recommendation and vote results).
Form 8-K filings announcing the transaction, closings, and material events (8-Ks typically provide the company’s press releases and material agreements).
Form 4 filings disclosing insider transactions and option exercises that occurred during the period surrounding the transaction.
Form 15-related filings (e.g., Form 15-12G) or other filings that signal termination of registration under the Securities Exchange Act for companies that cease public reporting; these filings document the effective cessation of reporting obligations and are commonly used when a U.S. company becomes privately held following a transaction.

As of April 2025, public records showed the company completed required filings consistent with the announced transaction; researchers should consult the SEC EDGAR database for the precise filings and dates for accd stock’s termination of registration and related disclosures.

Risks and controversies

The principal risks and controversies that applied to Accolade and that investors commonly associated with accd stock while it was public included:

Business concentration: A reliance on employer and payor customers means revenue and renewal risk tied to a concentrated customer set and long sales cycles.
Competitive landscape: The virtual care, benefits navigation and health-technology markets are competitive, with multiple companies offering overlapping services. Market share and margin pressure were common concerns.
Profitability and cash burn: Accolade reported negative EPS in recent periods leading into 2025; profitability trends and cash runway were scrutinized by investors and analysts.
Regulatory risk: The healthcare industry is highly regulated; changes in Medicaid/Medicare policy, employer benefit rules, privacy or telehealth regulation could impact the business.
Transaction risk: For accd stock holders, the primary transaction-related risks included execution risk around closing, final per-share consideration, tax consequences for shareholders receiving cash, and loss of public-market liquidity once the company delisted.

No material cybersecurity breach or nation-state political controversy tied to Accolade’s public filings was cited in mainstream market coverage up to April 2025; researchers should review company 8-Ks and risk disclosures for any updates.

Timeline of key events

2007 — Accolade founded.
[various product and partnership milestones during the 2010s; see company filings for an itemized history].
March 27, 2025 — Shareholders reported to have approved the merger with Transcarent (source: company proxy materials and press reporting as of that date).
April 8, 2025 — Company and public reports indicated the merger had closed and the combined entity’s ownership structure was effective; subsequent filings documented steps to terminate public reporting and delist ACCD (source: company announcement and SEC filings reported in April 2025).
April 2025 — Form(s) related to termination of registration and delisting were publicly filed with the SEC reflecting the post-transaction status.

This timeline summarizes the most consequential corporate events for accd stock through April 2025; earlier operational and product milestones are available in company investor materials and annual reports.

References

The facts and dates in this article rely on reporting and market-data pages available as of April 2025. The following sources were used for market metrics, transaction coverage and filings summaries (source names only; readers should consult the cited providers for archived materials):

Investing.com — price and market metrics snapshots for accd stock (used for price and volume references).
Yahoo Finance — company overview, financial summaries and historical quotes for accd stock.
MarketBeat — analyst coverage summaries and consensus metrics for accd stock.
StockTitan — news archive and transaction coverage pieces referring to the Accolade–Transcarent merger.
Stocktwits — social sentiment feed referencing accd stock activity leading up to the vote and closing.
Barchart — market-data pages and historical quote tables for accd stock.
ADVFN — quote pages and SEC filing cross-references for accd stock.
Webull — market-data snapshots and delisting notes reported in April 2025.
Public.com — investor commentary and aggregated public-market data referencing accd stock and the transaction.

Note: Specific dates called out in this article (e.g., March 27, 2025 shareholder vote and April 8, 2025 closing) are documented in the company’s public statements and market coverage reported in early April 2025. For legally definitive text, refer to the company’s SEC filings (proxy statements, Form 8-Ks, and Form 15-series filings) filed in March–April 2025.

Important disclaimers and guidance for former accd stock holders

Trading status: Following the closing reported in April 2025, accd stock ceased public trading on NASDAQ and the company terminated certain public-reporting obligations through the appropriate SEC filings. Public shareholders received the consideration described in the transaction documents; confirmation of receipts and tax consequences depend on brokerage and settlement processes.
Documentation: Shareholders and researchers should retain or request transaction confirmations from their broker-dealer or custodian showing the per-share consideration paid and settlement date. For registrants and those seeking tax treatment guidance, consult a tax professional and the company’s transaction documents.
Not investment advice: This article is informational and not financial, tax, or legal advice. Readers should consult licensed professionals for personal guidance.

Closing and next steps

For readers researching accd stock history and the 2025 corporate transaction, the most actionable next steps are:

Review the company’s definitive proxy statement and Form 8-K filings dated around March–April 2025 for precise transaction terms and effective dates (search SEC EDGAR for Accolade filings from those dates).
Check your brokerage account or custodian statements to confirm transaction settlement and receipt of cash consideration per the deal terms (the reported cash-per-share amount was approximately $7.03 as reported in market coverage of the closing).
Use Bitget’s market tracking and Bitget Wallet to monitor related companies, healthcare-tech industry movers and any post-transaction communications that affect investor records.

Explore Bitget’s research and portfolio tools to consolidate updates and keep watchlists current. For archival research on accd stock, consult the market-data providers and the SEC filings described above.

All factual statements in this article are based on public reporting and filings available through April 2025. Dates and numeric figures are indicated where applicable; for definitive legal terms and exact financial numbers, consult the company’s SEC filings and official investor materials.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.